HFpEF HFmrEF
Conditions
Interventions
Sponsors
The Second Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18–80 years, male or female; 2.Patients with a definite diagnosis of heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) established at the Department of Cardiology, The Second Xiangya Hospital of Central South University; 3.Outpatients or inpatients who, based on routine clinical diagnostic needs, had already undergone coronary computed tomography angiography (CCTA) to exclude coronary artery disease as the primary etiology of heart failure, and cardiac magnetic resonance (CMR) imaging to evaluate the nature of myocardial pathology, with complete original imaging data available for analysis. 4.Prior to enrollment, the patients or their legally authorized representatives had fully understood the study content, potential risks, and anticipated benefits, and had voluntarily signed the written informed consent form.
Exclusion criteria
Exclusion criteria: 1.Acute myocardial infarction or severe coronary artery disease: patients with acute myocardial infarction, or those with left main coronary artery stenosis =50% as indicated by coronary computed tomography angiography (CCTA) or invasive coronary angiography (ICA). 2.Other specific cardiac diseases: severe valvular heart disease (e.g., severe aortic stenosis, severe mitral regurgitation), congenital heart disease, constrictive pericarditis, acute myocarditis, or pericarditis. 3.Specific cardiomyopathies: hypertrophic obstructive cardiomyopathy (HOCM), or cardiac involvement in sarcoidosis. 4.Severe organ dysfunction: severe renal dysfunction (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m²), or severe hepatic failure (Child-Pugh class C). 5.Systemic inflammation and malignancy: acute infection within the past 3 months; active autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis); or a history of malignancy with a life expectancy of <2 years. 6.Others: pregnant or breastfeeding women; or patients currently participating in other interventional clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Coronary perivascular fat attenuation index (FAI);Major adverse cardiovascular events (MACE); | — |
Secondary
| Measure | Time frame |
|---|---|
| Epicardial adipose tissue (EAT) volume and density, plaque volume (PV), and percent atheroma volume (PAV);E/e' ratio and left atrial volume index (LAVI);Myocardial blood flow (MBF), myocardial perfusion reserve (MPR), and extracellular volume (ECV); | — |
Countries
China
Contacts
Public ContactYu Bilian
The Second Xiangya Hospital of Central South University
Outcome results
None listed